Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - a single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines

Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - a single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines

<strong>Background<br></strong> Heterologous COVID vaccine priming schedules are immunogenic and effective. This report aims to understand the persistence of immune response to the viral vectored, mRNA and protein-based COVID-19 vaccine platforms used in homologous and heterologous...

Full description

Bibliographic Details
Main Authors: Shaw, RH, Greenland, M, Stuart, AS, Aley, PK, Andrews, NJ, Cameron, JC, Charlton, S, Clutterbuck, EA, Collins, AM, Darton, T, Dinesh, T, Duncan, CJ, Faust, SN, Ferreira, DM, Finn, A, Goodman, AL, Green, CA, Hallis, B, Heath, PT, Hill, H, Lambe, T, Libri, V, Lillie, PJ, Morey, E, Mujadidi, YF, Payne, R, Plested, EL, Provstgaard-Morys, S, Ramasamy, MN, Mary Ramsay, F, Read, RC, Hannah Robinson, RN, Screaton, GR, Singh, N, Turner, DP, Turner, PJ, Rachel White, RN, Nguyen-Van-Tam, JS, Liu, X, Snape, MD
Other Authors: Com-COV2 Study Group
Format: Journal article
Language:English
Published: Elsevier 2023

Similar Items